04:31 PM EDT, 03/14/2024 (MT Newswires) -- Allogene Therapeutics ( ALLO ) reported late Thursday a Q4 net loss of $0.51 per diluted share, narrowing from $0.67 a year ago.

Analysts polled by Capital IQ expected a loss of $0.45.

Collaboration revenue for the quarter ended Dec. 31 was $21,000, compared with $26,000 a year earlier. Analysts surveyed by Capital IQ expected $20,000.

The clinical-stage drugmaker said it continues to expect its cash runway to fund operations into 2026.

Price: 4.48, Change: -0.01, Percent Change: -0.33